Brief description of the product/ process/ service

PrecizionIQ offers three complementary product formats for non-invasive prenatal chromosomal abnormality detection, designed to serve different stages of market and healthcare-system readiness: 1. DBS-based LC-MS Test (Dried Blood Spot, Liquid Chromatography–Mass Spectrometry): A high-precision metabolomics test using dried blood spot sampling analyzed via LC-MS, deployed initially through centralized partner laboratories in major metropolitan centers to ensure standardized quality control as the platform scales. 2. ELISA-based Test: A laboratory-compatible test format that enables deployment within existing diagnostic lab ecosystems, supporting decentralized rollout through major diagnostic chains (e.g., Dr. Lal PathLabs, SRL, Metropolis, Apollo) and hospital networks for wider geographic reach. 3. LFA-based Test (Lateral Flow Assay): A simplified, low-cost rapid test format designed for population-scale access, projected at under ₹1,500 per test, enabling deployment in Tier-2/3 cities, OB-GYN clinics, maternity centers, and government maternal health programs as part of routine antenatal care.